McNeil presses FDA on analgesic/sleep-aid combo
This article was originally published in The Tan Sheet
The Johnson & Johnson subsidiary asks FDA to consider data supporting a Nighttime Sleep-Aid OTC monograph indication for "relief of occasional sleeplessness when associated with minor aches and pains" in a drug product containing diphenhydramine and acetaminophen - such as McNeil's Tylenol PM. The firm's March 31 1letter notes it generated data on the drug combination's effects using the same model Wyeth used to generate data in support of the new drug application for Advil PM (ibuprofen/diphenhydramine), which launched in 2006 to challenge Tylenol PM (2"The Tan Sheet" Jan. 9, 2006). McNeil's letter follows FDA's recent 3determination that data on diphenhydramine and acetaminophen the Consumer Healthcare Products Association submitted were insufficient to demonstrate "'each active ingredient makes a contribution to the claimed effect(s)' as required by the OTC combination policy.
You may also be interested in...
Wyeth is entering the combination sleep aid/pain reliever category with its new Advil PM, recently approved by FDA for over-the-counter sale
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.